The FSUE Moscow Endocrine Plant - ENDOPHARM signed an agreement with the Swiss manufacturer LIPOMED, becoming its exclusive partner in the distribution of reference standards in the Russian Federation and a number of CIS countries. The agreement is mutually beneficial in terms of economic and image aspects.
As a developer and manufacturer of medicines for treatment of rare diseases LIPOMED (www.lipomed.com) also specializes in the production of a wide range of reference standards, most of which are analytical (reference) standards of controlled agents and substances. Reference standards of this category are intended for use in expert, operational-search, scientific, educational activities, during medical examinations, etc.
Production of reference standards by LIPOMED is accredited by ISO/IEC 17025 and ISO 17034, certified according to the ISO9001 standard and meets the international requirements.
The agreements reached with the Swiss manufacturer do not affect the implementation by ENDOPHARM of its own strategic program for the introduction and production of domestic reference standards used in the Russian Federation. At present the Enterprise already produces 12 analytical and 11 reference standards of controlled agents and substances. At least one and a half dozen new titles are planned to be put into production by the end of 2021.
The ENDOPHARM laboratory is accredited for compliance with the requirements of the international standard ISO 17034, which confirms the scientific and technical competence of the Enterprise to produce reference standards that meet international quality standards, taking into account modern requirements for the organization of the production process.
The FSUE Moscow Endocrine Plant Is the Exclusive Distributor of Reference Standards of the Swiss Manufacturer LIPOMED in the Russian Federation and CIS countries
31 March 2021
Comment type is not specified in the component properties.